Quoin Pharmaceuticals (QNRX) announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 ...

Fourth Quarter 2024 Highlights On Dec. 20, 2024, Quoin announced the successful completion of a $6.8 million public offering, bolstering the company’s financial position to support ongoing clinical ...

QUOIN PHARMACEUTICALS ($QNRX) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.35 per share, beating estimates of -$0. ...

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) is anticipated to post its quarterly earnings results before the market ...

对Cellect Biotechnology ADR来说，这是充满挑战的一年。该公司股票QNRX已跌至52周新低，仅为0.28美元，市值仅为624万美元。根据 InvestingPro 分析，该股票目前的交易价格低于其公允价值，尽管出现下跌，但可能存在投资机会。这一显著下跌反映了该生物科技公司的整体趋势，过去一年股价下跌了81.13%。该公司贝塔系数为1.59，流动比率为3.02，显示出较高的波动 ...

ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and ...

March 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ASHBURN, Va., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company” or "Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan ...

Eastern quolls at Bonorong after successful conservation translocation of 24 eastern quolls to The Quoin in the Midlands. 3 ...